Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, topical finasteride showed mild-to-moderate improvement in androgenetic alopecia among a cohort in Saudi Arabia, with combination therapy outperforming monotherapy. Adverse events were rare. The study highlights the need for prospective trials to clarify finasteride's standalone effects.

In this study, a combination of 5% minoxidil lotion and 0.25% topical finasteride spray significantly increased hair density and improved photographic assessments in men with androgenetic alopecia compared to the treatments used alone, with all methods showing good tolerability.

This article reviews treatment options for male androgenetic alopecia, including their distinct aims of arresting progression, stimulating regrowth, and concealing hair loss, and reports no new clinical results.

This review discusses the safety of dermatological medications used during pregnancy, highlighting that retinoids have strong teratogenic risks and should be used with caution; it reports no new clinical results.

This study found that using a topical zinc-thymulin spray on the scalp for more than 6 months was safe and significantly improved hair growth in adults with male pattern baldness, with notable increases in certain hair types and no reported adverse effects.

This report describes a case of prolonged distributive shock attributed to minoxidil overdose, which involved intentional ingestion alongside trauma and NSAIDs, successfully managed with medications and hydration despite persistent low blood pressure.

This review found that topical finasteride has similar efficacy to oral finasteride in treating male and female pattern hair loss, with fewer systemic side effects, mainly causing localized scalp reactions like irritation and erythema.

This study reviewed existing literature on Androgenetic Alopecia treatments, finding that minoxidil promotes hair growth but can cause side effects due to its traditional formulations. Novel delivery systems like film-forming sprays may reduce these side effects and enhance efficacy.

This meta-analysis found that the combination of topical minoxidil-finasteride was more effective than minoxidil alone in improving hair density, hair diameter, and global photographic assessment for male androgenetic alopecia, though larger standardized trials are needed to confirm long-term outcomes.

This review discusses the emerging pathophysiological factors and potential new therapies for androgenetic alopecia beyond traditional treatments, but reports no new results.

This study found that the MorrF topical solution combination showed significantly better hair growth improvements than Minoxidil alone in male patients with Androgenetic Alopecia.

This study demonstrated that using finasteride impurity as a non-isotopically labeled internal standard in paper spray ionization–mass spectrometry can effectively and efficiently measure finasteride tablet dissolution, achieving results comparable to high-performance liquid chromatography.

This study found that using minoxidil 2% as a mesotherapy injection showed more significant improvement in treating androgenetic alopecia in female patients than topical application.

This study found that the developed Finasteride-loaded SMEDDS improved the relative bioavailability of the drug compared to a commercial tablet, offering a promising oral delivery system for glucosteroid analogs.

This randomized, double-blind, placebo-controlled phase III trial found that a 24-week treatment with topical finasteride significantly increased hair growth and was well-tolerated in Chinese men with androgenetic alopecia compared to placebo.

This study compared the effectiveness of topical finasteride, oral finasteride, and topical minoxidil over 12 months in postmenopausal women with androgenetic alopecia, exploring their therapeutic effects on this population. Results are not reported in the abstract.

This study found that topical finasteride mixed with minoxidil improved hair appearance and self-esteem in men with androgenetic alopecia, but it was not superior to oral finasteride and had lower treatment adherence.

In this study, the addition of a topical gel containing growth-factor mimicking oligopeptides and other ingredients showed improved efficacy in subjects with androgenic alopecia using minoxidil or finasteride compared to drug treatment alone.

This study found that a nanostructured lipid carrier gel containing Minoxidil and Finasteride met desired criteria for stability and performance, suggesting it may be an effective topical treatment for hair loss, especially in extreme conditions.

The combination of finasteride and minoxidil is as safe and effective as minoxidil alone for improving hair growth in men.

This study found topical finasteride and minoxidil both improved hair loss clinically and trichoscopically more effectively than spironolactone in women with female pattern hair loss.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This study assessed the effectiveness of various combinations of minoxidil with other agents for androgenetic alopecia, finding that platelet-rich plasma and basic fibroblast growth factor combined with minoxidil significantly increased hair density, while different combinations were optimal depending on gender.

The topical finasteride spray was safe and well-tolerated with stable effects.

This article discusses androgenetic alopecia in men and reports that finasteride at 1 mg/day for 24 months is generally well tolerated and may effectively inhibit hair loss.

This study found that aqueous extract of Pueraria mirifica, when administered to a rat model, significantly reduced prostate weight, prostatic index, and serum dihydrotestosterone levels, while also improving prostate histomorphology, suggesting its potential as an anti-BPH treatment.

In this narrative review, researchers reported that oral finasteride significantly improved hair count and density in male androgenetic alopecia but had higher systemic exposure and potential side effects compared to topical formulations, which provided similar efficacy with lower systemic DHT suppression.

This source reports that combining 5-alpha reductase inhibitors with minoxidil for treating male androgenic alopecia presents a minimal risk of side effects when administered following established medical guidelines, with finasteride commonly associated with reversible sexual side effects and dutasteride used off-label with similar risks.

This review discusses the development of an algorithmic guideline for treating androgenetic alopecia in Asian patients, using the BASP classification to address limitations of previous guidelines, and reports no clinical results.

This review focuses on the medical treatment of common nonscarring alopecias, including androgenetic alopecia, alopecia areata, and telogen effluvium, and reports no new clinical results.